GLP1R and type 2 diabetes mellitus: In parallel, the advent of sodium–glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has reshaped the management of type 2 diabetes, shifting the paradigm from glucose-centric control toward comprehensive cardiorenal risk reduction [6,7,8].